Compare HQI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | ACRV |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | 65000 | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.0M | 47.6M |
| IPO Year | 2008 | 2022 |
| Metric | HQI | ACRV |
|---|---|---|
| Price | $11.29 | $1.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $13.00 | $13.00 |
| AVG Volume (30 Days) | 11.8K | ★ 906.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.29% | N/A |
| EPS Growth | N/A | ★ 13.14 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $34,598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.34 |
| P/E Ratio | $31.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $1.05 |
| 52 Week High | $13.78 | $5.65 |
| Indicator | HQI | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 48.13 |
| Support Level | $10.29 | $1.49 |
| Resistance Level | $11.99 | $1.86 |
| Average True Range (ATR) | 0.68 | 0.11 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 10.41 | 51.69 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.